Aimmune Therapeutics (NASDAQ:AIMT) had its price objective lowered by Credit Suisse Group from $19.00 to $15.00 in a research note published on Wednesday morning, AnalystRatings.com reports. The brokerage currently has a neutral rating on the biotechnology company’s stock.
Other analysts also recently issued reports about the stock. Cowen started coverage on shares of Aimmune Therapeutics in a research report on Monday, July 13th. They set an outperform rating and a $35.00 price target on the stock. Wedbush reissued a buy rating and set a $66.00 target price on shares of Aimmune Therapeutics in a report on Wednesday, May 13th. HC Wainwright decreased their price target on Aimmune Therapeutics from $30.00 to $15.00 and set a neutral rating for the company in a research note on Tuesday, May 12th. BidaskClub downgraded Aimmune Therapeutics from a sell rating to a strong sell rating in a research note on Friday, July 10th. Finally, Zacks Investment Research cut Aimmune Therapeutics from a hold rating to a sell rating in a research note on Monday, July 27th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and seven have given a buy rating to the stock. The company has an average rating of Hold and an average target price of $37.00.
Shares of Aimmune Therapeutics stock opened at $13.21 on Wednesday. The company has a quick ratio of 8.01, a current ratio of 8.10 and a debt-to-equity ratio of 0.59. Aimmune Therapeutics has a 1-year low of $10.09 and a 1-year high of $37.00. The business’s fifty day moving average price is $16.60 and its two-hundred day moving average price is $19.93.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Thursday, July 30th. The biotechnology company reported ($1.06) EPS for the quarter, meeting analysts’ consensus estimates of ($1.06). On average, analysts predict that Aimmune Therapeutics will post -4.47 EPS for the current fiscal year.
Several large investors have recently added to or reduced their stakes in AIMT. Eventide Asset Management LLC increased its stake in Aimmune Therapeutics by 24.9% in the 1st quarter. Eventide Asset Management LLC now owns 3,851,000 shares of the biotechnology company’s stock worth $55,531,000 after purchasing an additional 767,000 shares in the last quarter. Norges Bank acquired a new position in shares of Aimmune Therapeutics in the fourth quarter worth about $16,532,000. Morgan Stanley increased its position in shares of Aimmune Therapeutics by 84.4% in the first quarter. Morgan Stanley now owns 1,018,692 shares of the biotechnology company’s stock worth $14,689,000 after acquiring an additional 466,231 shares in the last quarter. Avidity Partners Management LP acquired a new stake in shares of Aimmune Therapeutics during the first quarter valued at approximately $5,883,000. Finally, Two Sigma Investments LP purchased a new stake in shares of Aimmune Therapeutics in the 1st quarter valued at approximately $4,150,000. Institutional investors and hedge funds own 72.43% of the company’s stock.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Recommended Story: Margin
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.